Ambros Therapeutics
Last verified 2026-05-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $154.0Mattributed |
|---|---|
| Latest round | series-a, $125.0M, 2025-12-01attributed |
| Founded | 2024 |
| Headquarters | 1-10 |
| Industry | series-a |
| Stage | series-a |
| Website | ambrosrx.com |
Ambros Therapeutics is a clinical-stage biotech advancing neridronate, a non-opioid bisphosphonate, through Phase 3 for complex regional pain syndrome type 1. It serves CRPS-1 patients facing severe unrelenting pain with no FDA-approved drugs available. Backed by RA Capital and Enavate Sciences.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-01 | series-a | $125.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $125.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $154.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | ambrosrx.com, read 2026-05-16 |
| Description | self-reported | ambrosrx.com, read 2026-05-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.